AŞILAMANIN COVID-19 ÖLÜMLERİNE ETKİSİ: ÜLKELERİN GELİR GRUPLARINA GÖRE BİR ARAŞTIRMA

Year 2023, Volume: 10 Issue: 1, 101 - 116, 29.03.2023

Osman Şenol , Ümit Çıraklı , Durmuş Gökkaya

https://doi.org/10.30798/makuiibf.1033552

Abstract

Bu çalışma, farklı gelir düzeylerine sahip ülkelerde Covid-19 aşısının Covid-19 kaynaklı ölümler üzerindeki etkilerini ortaya koymayı amaçlamaktadır. Bu kapsamda çalışma, 01.03.2021 ile 08.08.2021 tarihleri arasındaki verileri Panel veri analizi ile incelemiştir. Araştırmada ilk olarak ülkeler gelir gruplarına göre alt gelir düzeyi, orta gelir düzeyi ve yüksek gelir düzeyi olmak üzere üç farklı kategoriye ayrılmıştır. Bu nedenle her ülke grubu ayrı ayrı incelenmiş ve üç farklı ekonometrik model üretilmiştir. Araştırmanın sonuçlarına göre aşılanan nüfusta yüzde 1'lik bir artış, düşük gelirli ülkelerde Covid-19'dan ölüm sayısında yüzde 2,1'lik, orta gelirli ülkelerde yüzde 0,5'lik ve yüksek gelirli ülkelerde %13'lük bir düşüşe yol açacaktır. Yüksek Araştırmanın sonuçlarına göre aşının Covid-19 kaynaklı ölümleri önemli ölçüde azaltacağı sonucuna varılmıştır. Bu nedenle kişilerin aşı dozlarını olabildiğince hızlı tamamlamaları önerilmektedir.

Keywords

Covid-19 vaccination, Covid-19 deaths, Vaccination, Panel data analysis

THE EFFECT OF VACCINATON ON COVID-19 DEATHS: A RESEARCH ACCORDING TO COUNTRIES' INCOME GROUPS

Abstract

This study aims to reveal the impacts of Covid-19 vaccination on Covid-19 based deaths in countries with different income levels. In this context, the study investigated data between 01.03.2021 and 08.08.2021 by Panel data analysis. In the research, firstly, countries were divided into three different categories according to income groups: low-income level, middle-income level and high-income level. Therefore, each country group was examined separately and three different econometric models were produced. According to the results of the research, a 1% increase in the population vaccinated will result in a 2.1% decrease in the number of deaths from Covid-19 in low-income countries, a 0.5% decrease in middle-income countries and a 13% decrease in high-income countries. According to the results of the research, it was concluded that vaccination will significantly reduce deaths from Covid-19. For this reason, it is recommended that people complete their vaccine doses as fast as possible.

Keywords

Covid-19 vaccination, Covid-19 deaths, Vaccination, Panel data analysis

References

• Açıkgöz, E., Uygurtürk, H., & Korkmaz, T. (2015). Analysis of factor affecting growth of pension mutual funds in Turkey. International Journal of Economics and Financial Issues, 5(2), 427-433.
• Baden, L. R., El Sahly, H. M., Essink, B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England Journal of Medicine, 384(5), 403-416. https://doi.org/10.1056/NEJMoa2035389
• Brien, R. M. (2007). A caution regarding rules of thumb for variance inflation factors. Quality & Quantity 2007, 41(5), 673-690. https://doi.org/10.1007/s11135-006-9018-6
• Cirakli, U., Dogan, I., & Gozlu, M. (2021). The Relationship Between COVİD-19 Cases and COVID-19 Testing: a Panel Data Analysis on OECD Countries. Journal of Knowledge Economy. https://doi.org/10.1007/s13132-021-00792-z
• Erkekoğlu, P., Erdemli Köse, S. B., Balcı, A., & Yirün, A. (2020). Vaccine Hesitancy and Effects of COVİD-19. Journal of Literature Pharmacy Sciences, 9(2), 208-20. https://doi.org/10.5336/pharmsci.2020-76102
• Gujarati, D. N. (2004). Basic econometrics. McGraw Hill: New York.
• Gürbüz, S., Aydın, S., & Çöl, M. (2021). COVİD-19 Aşı Çalışmaları ve Uygulamaları. In: Yeni Koronavirüs Pandemisi Sürecinde Türkiye’de Covid-19 Aşılaması ve Bağışıklama Hizmetlerinin Durumu (pp. 45-60). Ankara: Türk Tabipler Birliği.
• Kumar, R., Nagpal, S., Kaushik, S., & Mendiratta, S. (2020). COVID-19 Diagnostic Approaches: Different Roads to the same Destination. VirusDisease, 31(2), 97–105. https://doi.org/10.1007/s13337-020-00599-7
• Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., et al. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVİD-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 397(10275), 671-681. https://doi.org/10.1016/S0140-6736(21)00234-8
• Ministery of Health of Republic of Turkey. (2021). Vaccination table of Turkey. Retrieved May 8, 2021 from https://covid19asi.saglik.gov.tr/
• Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577
• Ryser, M. F. (2021). Pharmaceutical J. Safety and Efficacy of a Single Dose of Ad26.COV2.S: ENSEMBLE study results Janssen Pharmaceutical Companies of Johnson & Johnson. Retrived September 9, 2021 from https://cdn.who.int/media/docs/default-source/immunization/sage/2021/march/3--safety-and-efficacy-of-a-single-dose-of-ad26.cov2.s_ensemble-study-results.pdf?sfvrsn=e08df041_5
• Salathé, M., Althaus, C. L., Neher, R., Stringhini, S., Hodcroft, E., Fellay, J., et al. (2020). COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Swiss medical weekly, 150(11-12), w20225. https://doi.org/10.4414/smw.2020.20225
• SINOVAC. (2021). Summary of Clinical Trial Data of Sinovac’s COVİD-19 Vaccine (CoronaVac®)-SINOVAC - Supply Vaccines to Eliminate Human Diseases. Retrived September 10, 2021 from http://www.sinovac.com/?optionid=754&auto_id=927
• Voysey, M., Clemens, S. A. C., Madhi, S. A., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 397(10269), 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
• WHO. (2014). Report of the SAGE Working Group on Vaccine Hesitancy. Retrived September 10, 2021 from https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf
• World Health Organization- China Joint Mission on Coronavirus Disease 2019 (2020). Report of the WHO China Joint Mission on Coronavirus Disease 2019 (COVID-19). Retrived April 1, 2020 from https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
• Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., et al. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265-269. https://doi.org/10.1038/s41586-020-2008-3
• Yavuz, E. (2020). COVID-19 Vaccines. Türk Aile Hekimliği Dergisi, 24(4), 227-234. https://doi.org/10.15511/tahd.20.00427
• Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., et al. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine, 382(8), 727-733. https://doi.org/10.1056/ NEJMoa2001017